No Carolina / NY / Florida
Ph: 561.316.3330

Shimadzu Receives Vizient Contract for Cardiac and Vascular Interventional Systems and General Radiology Systems

Summation

  • Shimadzu currently has general diagnostic X-ray imaging equipment on contract with Vizient and available for purchase, and has been awarded a new agreement for these products that is effective on Oct 1, 2021, offering the following systems.
  • The Trinias unity edition is available in several configurations with both Floor and Ceiling mounted C-Arms to meet both Cardiac and Vascular requirements with a range of flat panel detectors, including 8″,12″.
  • Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc.

Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc., the nation’s largest health care performance improvement company, effective September 1, 2021.

The agreement for Trinias unity edition product line, which consists of the Cardiac and Vascular Interventional digital angiography systems, offers enhanced savings to Vizient members.

The Trinias unity edition is available in several configurations with both Floor and Ceiling mounted C-Arms to meet both Cardiac and Vascular requirements with a range of flat panel detectors, including 8″,12″ and 16″ sizes. Bi-Plane configurations for 8″ and 12″ are also available for Cardiac and Neurology. “Shimadzu intraoperative x-ray systems have some unique features that improve both operator efficiency and workflow as well as patient comfort and safety,” says Tim Stevener, Shimadzu’s Director of the IXR product line. Stevener goes on to say, “exclusive features like reciprocal space mapping-digital angiography system provides incredible images even if the patient unexpectantly moves, while STENTVIEW, using artificial intelligence, allows the physician to visualize even the smallest wires and stents used.”

Shimadzu currently has general diagnostic X-ray imaging equipment on contract with Vizient and available for purchase, and has been awarded a new agreement for these products that is effective on Oct 1, 2021, offering the following systems:

  • RADspeed PRO radiographic systems series featuring POWERGLIDE
  • MobileDaRt MX8 DR mobiles with Canon or Konica FPD’s
  • SONIALVISION G4LX – Advanced Universal RF system
  • FLUOROspeed X1 – Patient-side RF Table System

Tom Kloetzly, Vice President of National Sales and Marketing states, “With the contract for the Trinias unity edition, Shimadzu’s complete X-ray product portfolio is available to Vizient members nationally at contracted pricing.”

Vizient is the largest member-driven performance improvement company in the country. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers. Vizient membership represents more than $110 billion in annual purchasing volume.

More News

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy